BOTHELL, Wash., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that Bob Azelby, Alder’s president and chief executive officer, will provide a business overview and update at the 37 th Annual J.P. Morgan Healthcare Conference at 8:00 am PT on Tuesday, January 8, 2019 in San Francisco, CA.

Both the presentation and question and answer session that follows at 8:30 am PT will be webcast live on the Events & Presentations page of the Investors section of Alder's website at  http://www.alderbio.com , or by following the links below in your web browser. An archived replay of each webcast will be available on Alder's website for at least 30 days after each live event concludes.

About Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com .

Investor Relations Contact:                                         Michael Schaffzin Stern Investor Relations, Inc. 212.362.1200 michael@sternir.com

Media Contact:  Ashley Cadle TogoRun a.cadle@togorun.com 310.463.0143